Automation of end-to-end cell therapy

An automated, sealed cell engineering system optimizes CAR T cell production by integrating sensitive unit operations, reducing time and costs, and ensuring consistent product quality for widespread clinical use.

JP7863956B2Active Publication Date: 2026-05-22LONZA WALKERSVILLE INC +2
View PDF 5 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
LONZA WALKERSVILLE INC
Filing Date
2020-11-17
Publication Date
2026-05-22

AI Technical Summary

Technical Problem

The high manufacturing costs and process inefficiencies in generating chimeric antigen receptor T (CAR T) cells pose a barrier to their widespread clinical adoption, particularly due to the need for manual intervention in sensitive unit operations like cell activation, transduction, and expansion, which are critical for personalized medicine.

Method used

An automated method using a fully sealed cell engineering system to perform steps such as activating, transducing, expanding, and recovering immune cell cultures, optimized for cell density and conditions, with integrated sensors for real-time adjustments.

Benefits of technology

This approach reduces production time by a quarter, enhances product consistency, and ensures GMP compliance, making it feasible to scale up CAR T cell production for global patient populations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007863956000006
    Figure 0007863956000006
  • Figure 0007863956000007
    Figure 0007863956000007
  • Figure 0007863956000008
    Figure 0007863956000008
Patent Text Reader

Abstract

To provide automated methods of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.SOLUTION: A method for automated production of a genetically modified T cell culture comprises: (a) activating a T cell culture with an activation reagent to produce an activated T cell culture in a first chamber of the cell engineering system; and (b) transducing the activated T cell culture, the transducing comprising i. transferring the activated T cell culture from the first chamber to an electroporation unit via a first sterile, closed connection, ii. electroporating the activated T cell culture with a vector to produce a transduced T cell culture and iii. transferring the transduced T cell culture to a second chamber of the cell engineering system via a second sterile, closed connection.SELECTED DRAWING: Figure 3
Need to check novelty before this filing date? Find Prior Art